ORMDL3 Inhibitors
ORMDL3 inhibitors encompass a diverse group of chemicals that intricately modulate the activity of ORMDL3, a protein involved in sphingolipid metabolism and associated with asthma susceptibility. One key member of this class is Myriocin, a direct inhibitor that targets serine palmitoyltransferase (SPT), a crucial enzyme in sphingolipid biosynthesis. By inhibiting SPT, myriocin disrupts the synthesis of sphingolipids, leading to a downregulation of ORMDL3. This direct approach highlights the pivotal role of sphingolipid metabolism in the regulation of ORMDL3 expression. Additionally, indirect inhibitors like Imiquimod exemplify how modulation of immune response pathways can impact ORMDL3. Imiquimod, through Toll-like receptor 7 (TLR7) activation, triggers downstream signaling, including NF-κB, leading to suppression of ORMDL3 expression. This indirect modulation showcases the complex interplay between immune signaling and the regulation of ORMDL3 levels, underscoring the multifaceted regulatory mechanisms governing this protein.
The class of ORMDL3 inhibitors also includes compounds like GW843682X, which indirectly inhibits ORMDL3 by targeting the sphingolipid biosynthetic pathway through dihydroceramide desaturase (DEGS) inhibition. By disrupting sphingolipid synthesis, GW843682X downregulates ORMDL3, highlighting the intricate regulatory network governing ORMDL3 expression through lipid metabolism pathways. Fluphenazine, an indirect inhibitor, showcases the connection between neurotransmitter signaling and ORMDL3 regulation. By blocking dopamine receptors and disrupting downstream signaling cascades, including the AKT pathway, fluphenazine leads to the suppression of ORMDL3 expression. This highlights the intricate crosstalk between neuronal signaling and the regulation of ORMDL3. These examples collectively emphasize the diverse mechanisms by which chemicals can modulate ORMDL3, ranging from direct interference with sphingolipid metabolism to indirect regulation through immune response and neurotransmitter signaling pathways. Understanding these interactions provides valuable insights into the complex regulatory network governing ORMDL3 activity and its potential implications in respiratory health.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imiquimod | 99011-02-6 | sc-200385 sc-200385A | 100 mg 500 mg | $67.00 $284.00 | 6 | |
Imiquimod acts as an indirect inhibitor of ORMDL3 by modulating Toll-like receptor 7 (TLR7) signaling. Through TLR7 activation, imiquimod triggers downstream pathways, including NF-κB, leading to suppression of ORMDL3 expression. This chemical illustrates how modulation of immune response pathways can indirectly influence ORMDL3, emphasizing the intricate crosstalk between innate immunity and the regulation of ORMDL3 levels. | ||||||
Myriocin (ISP-1) | 35891-70-4 | sc-201397 | 10 mg | $150.00 | 8 | |
Myriocin directly inhibits ORMDL3 by targeting serine palmitoyltransferase (SPT), a key enzyme in sphingolipid biosynthesis. By inhibiting SPT, myriocin disrupts the synthesis of sphingolipids, leading to downregulation of ORMDL3. This chemical provides a direct approach to ORMDL3 inhibition through specific interference with the sphingolipid biosynthetic pathway, highlighting the importance of sphingolipids in the regulation of ORMDL3 expression. | ||||||
GW4869 | 6823-69-4 | sc-218578 sc-218578A | 5 mg 25 mg | $203.00 $611.00 | 24 | |
GW4869 indirectly inhibits ORMDL3 by targeting neutral sphingomyelinase (nSMase). Through inhibition of nSMase, GW4869 disrupts sphingomyelin metabolism, leading to decreased ORMDL3 expression. This chemical exemplifies how modulation of lipid metabolism pathways, specifically sphingolipid metabolism, can indirectly impact ORMDL3 levels, highlighting the intricate regulatory network governing ORMDL3 expression. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin serves as an indirect inhibitor of ORMDL3 by targeting phosphoinositide 3-kinase (PI3K) signaling. Through inhibition of PI3K, wortmannin disrupts downstream pathways, including the AKT pathway, leading to decreased ORMDL3 expression. This chemical illustrates how modulation of PI3K/AKT signaling can indirectly influence ORMDL3 levels, emphasizing the importance of signaling cascades in the regulation of ORMDL3 expression. | ||||||
Polo-like Kinase Inhibitor III | 660868-91-7 | sc-203202 | 500 µg | $109.00 | 1 | |
Polo-like Kinase Inhibitor III (GW843682X) indirectly inhibits ORMDL3 by targeting the sphingolipid biosynthetic pathway through inhibition of dihydroceramide desaturase (DEGS). By blocking DEGS, GW843682X disrupts sphingolipid synthesis, leading to downregulation of ORMDL3. This chemical provides a specific approach to indirectly inhibit ORMDL3 through modulation of sphingolipid metabolism, highlighting the importance of sphingolipids in the regulation of ORMDL3 expression. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
S1P serves as an indirect inhibitor of ORMDL3 by modulating sphingosine kinase activity. Through activation of sphingosine kinase, S1P triggers downstream signaling pathways, including the AKT pathway, leading to suppression of ORMDL3 expression. This chemical illustrates how modulation of sphingolipid metabolism, specifically the S1P pathway, can indirectly impact ORMDL3 levels, emphasizing the intricate regulatory network governing ORMDL3 expression. | ||||||
SB-334867 | 792173-99-0 | sc-507323 | 10 mg | $207.00 | ||
SB-334867 indirectly inhibits ORMDL3 by modulating orexin receptor signaling. By blocking orexin receptors, SB-334867 disrupts downstream signaling cascades, including the AKT pathway, leading to suppression of ORMDL3 expression. This chemical illustrates how modulation of neuropeptide signaling can indirectly influence ORMDL3 levels, emphasizing the intricate crosstalk between neuroendocrine pathways and the regulation of ORMDL3 expression. | ||||||
Tyrphostin B42 | 133550-30-8 | sc-3556 | 5 mg | $26.00 | 4 | |
Tyrphostin B42 (AG-490) serves as an indirect inhibitor of ORMDL3 by targeting Janus kinase 2 (JAK2) signaling. Through inhibition of JAK2, AG-490 disrupts downstream pathways, including STAT, leading to suppression of ORMDL3 expression. This chemical illustrates the connection between inflammatory signaling and the regulation of ORMDL3, emphasizing the multifaceted regulatory mechanisms governing ORMDL3 levels. | ||||||